Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival

Mazzaglia, Peter J.; Berber, Eren; Milas, Mira; Siperstein, Allan

doi:10.1016/j.surg.2007.01.036

Cited by 234 publications

(135 citation statements)

References 27 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…Following recent advances in treatment options for malignant diseases, prognoses after treatment of metastatic gastrointestinal malignancies have been improved, particularly for liver metastases from colorectal and neuroendocrine cancer [16,18,19]. However, managing liver metastasis from gastric cancer remains a challenge; gastric cancer patients with liver metastasis demonstrate a median survival of less than 1 year with chemotherapy alone [20].…”

Section: Discussionmentioning

confidence: 99%

“…Meanwhile, for liver metastases from colorectal cancer and neuroendocrine tumors, surgical resection is the treatment of choice [12,13]. RFA, a localized application of thermal energy that induces coagulation necrosis and thereby tumor cell destruction, has also been used to treat primary liver malignancies and liver metastasis from other organ malignancies, including colorectal, breast, and neuroendocrine cancer [14][15][16].…”

Section: And Woo Jin Hyungmentioning

confidence: 99%

See 1 more Smart Citation

Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation

et al. 2015

View full text Add to dashboard Cite

Background Although various liver-directed treatment modalities, such as liver resection and radiofrequency ablation (RFA), have been applied to treat liver metastases from gastric cancer, optimal management of them remains controversial. In patients with liver metastasis from gastric cancer, we investigated the short-and long-term outcomes of liver resection and RFA and analyzed factors influencing survival. Methods A total of 98 gastric cancer patients with liver metastasis and no extrahepatic disease were treated by liver resection (n = 68) or RFA (n = 30). Short-and long-term outcomes were evaluated retrospectively for each of the liver-directed treatments. Results Severe complication rates did not differ between liver resection (18 %) and RFA (10 %) (p = 0.333). Only one treatment-related mortality occurred in the liver resection group. No statistically significant difference in survival was noted between the treatment groups. Median overall survival after liver resection was 24 months, with 3-year overall and progression-free survival rates of 40.6 % and 30.4 %, respectively. Median overall survival after RFA was 23 months, with 3-year overall and progression-free survival rates of 43.0 % and 37.4 %, respectively. Only the size of the metastases was shown to be an independent prognostic factor for gastric cancer patients with liver metastasis. Conclusions In select patients with liver metastasis from gastric cancer, liver resection and RFA showed satisfactory and comparable short-and long-term results. Thus, systemic chemotherapy may not be the only therapeutic option for patients with liver metastasis, and possible liver-directed treatment options for such patients should be considered on an individual basis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: And Woo Jin Hyungmentioning

confidence: 99%

Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[26][27][28] Most of them are single institution in nature. Zhang et al reported their 10 year disease-free and overall survivals of 15% and 33% in HCC patients, respectively.…”

Section: Discussionmentioning

confidence: 99%

Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors

Sucandy

Cheek

Golas

et al. 2016

HPB

View full text Add to dashboard Cite

show abstract

“…Mazzaglia et al [7] reported a prospective trial of 80 RFA sessions which was performed in 63 patients with NELM. Tumor types included 36 "carcinoid", 18 pancreatic islet cell, and 9 medullary thyroid cancer.…”

Section: Radiofrequency Thermal Ablation (Rfa)mentioning

confidence: 99%

Long-term Survival in Patient with Metastatic Pancreatic Neuroendocrine Tumor Treated by Variable Treatment

Kang¹,

Ryu²,

Lee³

et al. 2017

Korean J Pancreas Biliary Tract

View full text Add to dashboard Cite

Well-to-moderately differentiated neuroendocrine tumors of gastroesophageal and pancreatic origin (GEP-NETs) with liver metastasis are a heterogeneous group of malignancies for which a range of therapeutic options have been employed. Surgical resection of hepatic metastases or hepatic artery embolization may be beneficial in patients with hepatic-predominant metastatic disease. Patients with "carcinoid" syndrome and syndromes associated with functional pancreatic NET (PNET) can be effectively treated with somatostatin analogs. On the other hand, the efficacy of systemic chemotherapy for these patients is limited. A placebo-controlled, double-blind, prospective, and randomized study showed that octreotide LAR improves progression-free survival in patients with advanced midgut functional "carcinoids." In patients with advanced pancreatic NET, randomized, placebo-controlled studies have recently demonstrated that treatment with the tyrosine kinase inhibitor sunitinib or with mTOR inhibitor everolimus is associated with improved progression-free survival. Based on these studies, octreotide LAR, sunitinib, or everolimus are now considered as first-line therapeutic options in patients with advanced NET. Future studies will likely further define the role of these agents in patients with carcinoid liver metastasis and pancreatic NET liver metastasis.

show abstract

Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival

Cited by 234 publications

References 27 publications

Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation

Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation

Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors

Long-term Survival in Patient with Metastatic Pancreatic Neuroendocrine Tumor Treated by Variable Treatment

Contact Info

Product

Resources

About